Didier Raoult

French scientist who championed anti-malaria drug for Covid-19 accused of falsifying test results

France — Investigation

Staff working under French microbiologist Didier Raoult, who last year attracted worldwide attention, and notably from Donald Trump, with his claims that the anti-malaria drug hydroxychloroquine was an effective medication for the prevention and treatment of Covid-19, have accused him of falsifying biological test results to support his assertions. Pascale Pascariello reports.

French scientist who pushed unproven Covid drug may have to quit post

France — Link

Didier Raoult, who promoted hydroxychloroquine treatment, may not be able to continue his research as he has reached retirement age. 

French professor faces disciplinary case over hydroxychloroquine claims

France — Link

Didier Raoult stands accused of touting drug as a coronavirus treatment without evidence

Covid-19: the questions over French professor who claims a cure

France — Investigation

As the Covid-19 pandemic continues its devastating path across the world, wreaking close to 200,000 recorded deaths from the virus and a global economic meltdown, the only evident hopes for a stabilised return to normal activity lies in a vaccine or a drug treatment to contain its spread. But few believe a vaccine will be realistically ready before, at the earliest, 2021. French microbiologist Didier Raoult has championed an immediately available antiviral compound called chloriquine, previously used against malaria, as a miracle drug that neutralises the virus, receiving the support of US President Donald Trump and last week hosting a visit to his laboratory by French President Emmanuel Macron. But as Pascale Pascariello reports, deep controversy surrounds the work of Raoult, a maverick amid France’s scientific establishment.

Chloroquine: the controversial drug at the heart of the race for a coronavirus treatment

France

In China and the United States, as well as France, the drug chloroquine is one of the main focal points in the race to provide an effective treatment for the Covid-19 coronavirus. So far there is still insufficient data to show whether this anti-malaria drug will prove useful in treating people infected with the virus. And a French study praising its benefits has become mired in controversy. Rouguyata Sall reports.